Literature DB >> 1536629

Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity.

R A Rudick1, R M Ransohoff.   

Abstract

Autoantigen recognition by specific T cells may initiate a tissue-specific immune response in multiple sclerosis (MS), which is a chronic inflammatory demyelinating disorder. During subsequent nonspecific immune amplification, interleukin 1 beta and tumor necrosis factor alpha are released by cells of the monocyte/macrophage lineage, with the potential to influence profoundly immune regulation systemically or within the central nervous system. Regulation of monocyte inflammatory gene expression may be relevant to the pathogenesis of MS. We investigated spontaneous secretion of interleukin 1 beta, tumor necrosis factor alpha, and prostaglandin E2 with the use of monocytes that we isolated from patients with active (n = 9) and stable (n = 9) MS and from age-matched normal controls (n = 9). The patient groups with MS were matched for age, duration of MS, and disease severity. Patients with active disease were within weeks of the onset of a clinical exacerbation. Monocytes were isolated by density gradient centrifugation, followed by adherence to plastic tissue culture flasks, resulting in a highly purified adherent monocyte preparation. Monocytes from patients with active disease spontaneously secreted less tumor necrosis factor alpha and less prostaglandin E2 compared with that in patients with stable MS, while interleukin 1 beta levels were below the level of assay sensitivity. Levels of interleukin 1 beta and tumor necrosis factor alpha increased to similar levels in response to lipopolysaccharide (0.1 mg/L), indicating that altered cell viability could not account for the observed differences. In response to lipopolysaccharide, prostaglandin E2 levels increased more significantly in patients with stable than active MS, suggesting differential sensitivity to stimuli of arachidonic acid metabolism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1536629     DOI: 10.1001/archneur.1992.00530270079022

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  14 in total

1.  Complementary and alternative medicine for the treatment of multiple sclerosis.

Authors:  Vijayshree Yadav; Lynne Shinto; Dennis Bourdette
Journal:  Expert Rev Clin Immunol       Date:  2010-05       Impact factor: 4.473

2.  Correlation between interferon production and clinical disease activity in patients with multiple sclerosis.

Authors:  M Dettke; P Scheidt; H Prange; H Kirchner
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

Review 3.  Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  Xu Zhang; Raymond Hupperts; Marc De Baets
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

4.  Enzyme-linked immunospot assays provide a sensitive tool for detection of cytokine secretion by monocytes.

Authors:  M Kouwenhoven; V Ozenci; N Teleshova; Y Hussein; Y M Huang; A Eusebio; H Link
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

5.  Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).

Authors:  R Balabanov; D Lisak; T Beaumont; R P Lisak; P Dore-Duffy
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

Review 6.  Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder.

Authors:  Aaron P Turner; Kevin N Alschuler; Abbey J Hughes; Meghan Beier; Jodie K Haselkorn; Alicia P Sloan; Dawn M Ehde
Journal:  Curr Neurol Neurosci Rep       Date:  2016-12       Impact factor: 5.081

Review 7.  Differential contribution of microglia and monocytes in neurodegenerative diseases.

Authors:  Caroline Baufeld; Elaine O'Loughlin; Narghes Calcagno; Charlotte Madore; Oleg Butovsky
Journal:  J Neural Transm (Vienna)       Date:  2017-10-23       Impact factor: 3.575

8.  An analysis of peripheral type benzodiazepine receptors on blood mononuclear cells during high dose steroid treatment of multiple sclerosis.

Authors:  P Ferrero; P Rocca; P Benna; C De Leo; E Montalenti; L Ravizza; B Bergamasco
Journal:  Ital J Neurol Sci       Date:  1992-11

9.  Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis.

Authors:  M Ott; L Demisch; W Engelhardt; P A Fischer
Journal:  J Neurol       Date:  1993-12       Impact factor: 4.849

10.  Tumor necrosis factor beta (TNF-β) NcoI polymorphism is associated with multiple sclerosis in Caucasian patients from Southern Brazil independently from HLA-DRB1.

Authors:  A P Kallaur; S R Oliveira; A N C Simão; E R D de Almeida; H K Morimoto; J Lopes; L M Pelegrino; W L C J de Pereira; Daniele Frizon Alfieri; R M Andrade; S D Borelli; M A E Watanabe; D R Kaimen-Maciel; E M V Reiche
Journal:  J Mol Neurosci       Date:  2014-04-04       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.